Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia WU Knauf, T Lissichkov, A Aldaoud, A Liberati, J Loscertales, R Herbrecht, ... Journal of clinical oncology 27 (26), 4378-4384, 2009 | 606 | 2009 |
A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia MD Cappellini, V Viprakasit, AT Taher, P Georgiev, KHM Kuo, T Coates, ... New England Journal of Medicine 382 (13), 1219-1231, 2020 | 278 | 2020 |
Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A … MJ Manco-Johnson, CL Kempton, MT Reding, T Lissitchkov, S Goranov, ... Journal of Thrombosis and Haemostasis 11 (6), 1119-1127, 2013 | 210 | 2013 |
A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory … RZ Orlowski, L Gercheva, C Williams, H Sutherland, T Robak, T Masszi, ... American journal of hematology 90 (1), 42-49, 2015 | 159 | 2015 |
Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial WU Knauf, T Lissitchkov, A Aldaoud, AM Liberati, J Loscertales, ... British journal of haematology 159 (1), 67-77, 2012 | 151 | 2012 |
Effect of late prophylaxis in hemophilia on joint status: a randomized trial MJ Manco‐Johnson, B Lundin, S Funk, C Peterfy, D Raunig, M Werk, ... Journal of Thrombosis and Haemostasis 15 (11), 2115-2124, 2017 | 128 | 2017 |
PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A T Lissitchkov, L Rusen, P Georgiev, J Windyga, R Klamroth, L Gercheva, ... Haemophilia 23 (5), 697-704, 2017 | 58 | 2017 |
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy … R Greil, P Obrtlíková, L Smolej, T Kozák, M Steurer, J Andel, S Burgstaller, ... The Lancet Haematology 3 (7), e317-e329, 2016 | 57 | 2016 |
High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia … AL Petzer, D Wolf, D Fong, T Lion, I Dyagil, Z Masliak, A Bogdanovic, ... Haematologica 95 (6), 908, 2010 | 42 | 2010 |
Head‐to‐head comparison of the pharmacokinetic profiles of a high‐purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients … T Lissitchkov, M Matysiak, K Zavilska, P Laguna, L Gercheva, A Antonov, ... Haemophilia 19 (5), 674-678, 2013 | 40 | 2013 |
A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine®, a high‐purity factor IX concentrate, in patients with severe haemophilia B T Lissitchkov, M Matysiak, K Zavilska, P Łaguna, L Gercheva, A Antonov, ... Haemophilia 17 (4), 590-596, 2011 | 29 | 2011 |
Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies C Kelaidi, A Stamatoullas, O Beyne-Rauzy, E Raffoux, B Quesnel, ... Haematologica 95 (6), 892, 2010 | 28 | 2010 |
Bendamustine Versus Chlorambucil as First-Line Treatment in B Cell Chronic Lymphocytic Leukemia: An Updated Analysis from An International Phase III Study. WU Knauf, T Lissitchkov, A Aldaoud, A Liberati, J Loscertales, ... Blood 112 (11), 2091, 2008 | 24 | 2008 |
Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia AG Zhelyazkova, AB Tonchev, P Kolova, L Ivanova, L Gercheva Scandinavian journal of clinical and laboratory investigation 68 (6), 492-500, 2008 | 24 | 2008 |
Ropeginterferon alfa-2b induces high rates of clinical, hematological and molecular responses in polycythemia vera: two-year results from the first prospective randomized … H Gisslinger, C Klade, P Georgiev, D Krochmalczyk, L Gercheva, ... Blood 130, 320, 2017 | 22 | 2017 |
Bendamustine induces higher remission rates, prolongs progression free survival as well as time to next treatment, and improves overall survival for patients in complete … WU Knauf, T Lissitchkov, A Aldaoud, AM Liberati, J Loscertales, ... Blood 116 (21), 2449, 2010 | 22 | 2010 |
The BELIEVE trial: results of a phase 3, randomized, double-blind, placebo-controlled study of luspatercept in adult beta-thalassemia patients who require regular red blood … MD Cappellini, V Viprakasit, A Taher, P Georgiev, KHM Kuo, TD Coates, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 21 | 2018 |
Pharmacokinetic study of a high‐purity factor IX concentrate (Factor IX Grifols®) with a 6‐month follow up in previously treated patients with severe haemophilia B JA Aznar, N Cabrera, M Matysiak, K Zawilska, L Gercheva, A Antonov, ... Haemophilia 15 (6), 1243-1248, 2009 | 21 | 2009 |
Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma. RZ Orlowski, L Gercheva, C Williams, HJ Sutherland, T Robak, T Masszi, ... Journal of Clinical Oncology 30 (15_suppl), 8018-8018, 2012 | 20 | 2012 |
Randomized, controlled, parallel-group trial of routine prophylaxis versus on-demand treatment with rFVIII-FS in adults with severe hemophilia A (SPINART) MJ Manco-Johnson, CL Kempton, MT Reding, T Lissitchkov, S Goranov, ... J Thromb Haemost 11 (6), 1119-1127, 2013 | 19 | 2013 |